IL-33在头颈鳞状细胞癌中的表达及与预后的相关性

林瀚青; 文译辉; 文卫平

doi:10.13201/j.issn.1001-1781.2018.12.004

IL-33在头颈鳞状细胞癌中的表达及与预后的相关性

- 中山大学附属第一医院耳鼻咽喉科医院广州市耳鼻咽喉科学重点实验室(广州, 510080)
基金项目:
广东省自然基金（No：2015A030310236，No：2017A030310362）

详细信息

通讯作者: 文卫平,E-mail:wenwp@mail.sysu.edu.cn

中图分类号: R739.91

收稿日期: 2018-04-15

Correlation between prognosis and IL-33 expression in head and neck squamous cell carcinoma

- Department of Otolaryngology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou Key Laboratory of Otorhinolaryngology, Guangzhou, 510080, China

More Information

Corresponding author: WEN Weiping, E-mail: wenwp@mail.sysu.edu.cn

Received Date: 15 April 2018

摘要

摘要: 目的：探讨头颈部鳞状细胞癌（HNSCC）患者组织中IL-33的表达情况与肿瘤临床病理特征及患者预后的相关性。方法：手术获取20例HNSCC患者肿瘤组织及对应癌旁正常组织，应用实时荧光定量PCR、免疫组织化学检测IL-33在不同组织中的表达；选取就诊于中山大学附属第一医院的107例HNSCC患者进行随访，通过免疫组织化学评估肿瘤组织IL-33的表达与肿瘤临床病理特征及预后的关系。结果：正常组织中IL-33主要表达于上皮细胞，正常组织IL-33 mRNA以及蛋白表达明显高于肿瘤组织；T3~4期及晚期（Ⅲ~Ⅳ）患者肿瘤组织中IL-33表达水平比T1~2期及早期（Ⅰ~Ⅱ）低，高分化肿瘤组织中IL-33水平高于中分化及低分化组；IL-33高表达组比低表达组患者预后好。多因素分析显示IL-33水平能够作为预测HNSCC预后的独立指标。结论：IL-33与HNSCC患者肿瘤进展及预后密切相关，可作为独立预测指标，具有较大的临床价值。
- 头颈部肿瘤 /
- 癌,鳞状细胞 /
- 白细胞介素33 /
- 预后
Abstract: Objective: To determine the correlation between the expression of IL-33 and significance in cancer biologial and patient's prognosis in head and neck squamous cell carcinoma (HNSCC). Method: Twenty pairs of tumor tissue and adjacent normal tissue were collected. qRT-PCR and immunohistochemistry (IHC) were used to detect the expression of IL-33 mRNA and protein in tissues. Correlation between IL-33 expression with clinicopathologic features of 107 HNSCC patients were analyzed. Result: IL-33 mRNA and protein expression levels in normal tissue were higher than paired tumor tissue. IL-33 level was significantly lower in patients with advanced T stages, lymph node metastases and advanced clinical stages, IL-33 expression was higher in well-differentiated tumor than moderate or poor differentiated tumor. Low IL-33 expression predicts poor prognosis. Multivariate analysis indicated that IL-33 expression was an independent predictive factor. Conclusion: IL-33 is related with the clinicopathological features in HNSCC and could be an independent predictor of HNSCC prognosis.
- Head and neck neoplasms /
- carcinoma,squamous cell /
- interleukin-33 /
- prognosis

HTML全文

参考文献(15)

[1]	TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin,2015,65:87-108.
[2]	CRUSZ S M, BALKWILL F R. Inflammation and cancer:advances and new agents[J]. Nat Rev Clin Oncol, 2015,12:584-596.
[3]	PREFONTAINE D, LAJOIE-KADOCH S, FOLEY S, et al. Increased expression of IL-33 in severe asthma:evidence of expression by airway smooth muscle cells[J]. J Immunol, 2009,183:5094-5103.
[4]	YASUDA K, MUTO T, KAWAGOE T, et al. Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice[J]. Proc Natl Acad Sci U S A,2012,109:3451-3456.
[5]	LOHNING M, STROEHMANN A, COYLE A J, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function[J]. Proc Natl Acad Sci U S A,1998,95:6930-6935.
[6]	WALZL G, MATTHEWS S, KENDALL S, et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2(Th2)- but not Th1-driven immunopathology[J]. J Exp Med,2001,193:785-792.
[7]	CURRY J M, SPRANDIO J, COGNETTI D, et al. Tumor microenvironment in head and neck squamous cell carcinoma[J]. Semin Oncol, 2014,41:217-234.
[8]	SCHMITZ J, OWYANG A, OLDHAM E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J]. Immunity,2005,23:479-490.
[9]	MOUSSION C, ORTEGA N, GIRARD J P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo:a novel ‘alarmin’[J]? PLoS One,2008,3:e3331.
[10]	SCHIERING C, KRAUSGRUBER T, CHOMKA A, et al.The alarmin IL-33 promotes regulatory T-cell function in the intestine[J]. Nature,2014,513:564-568.
[11]	PASTORELLI L, GARG R R, HOANG S B, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis[J]. Proc Natl Acad Sci U S A, 2010,107:8017-8022.
[12]	GAO X, WANG X, YANG Q, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells[J]. J Immunol,2015,194:438-445.
[13]	MATZINGER P. The danger model:a renewed sense of self[J]. Science, 2002,296:301-305.
[14]	CHEN C C, KOBAYASHI T, IIJIMA K, et al. IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs[J]. J Allergy Clin Immunol,2017,140:1351-1363.e7.
[15]	DOMINGUEZ D, YE C, GENG Z, et al. Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer[J]. J Immunol, 2017,198:1365-1375.